Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
Tumor necrosis factor (TNF) inhibitors improved clinical outcomes for patients with psoriasis but are limited by their high cost. There are several biosimilar options approved for the treatment of psoriasis which provides a lower-cost alternative and the potential to increase treatment availability...
Saved in:
Main Authors: | Rachel C. Ruda (Author), Katherine A. Kelly (Author), Steven R. Feldman (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
by: Claudia Fabiani, et al.
Published: (2019) -
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
by: Megna M, et al.
Published: (2022) -
Biological medicinal products: reference and biosimilar products - selected issues
by: Bartosz Kobuszewski
Published: (2021) -
Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
by: Giampiero Girolomoni, et al.
Published: (2024) -
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
by: Liese Barbier, et al.
Published: (2022)